Ginkgo Bioworks Holdings annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings Free Cash Flow (FCF) History (DNA)
Ginkgo Bioworks Holdings reported −$178.7M in free cash flow for fiscal 2025, an increase of $203.4M from the previous fiscal year, with a free cash flow margin of −105.04%.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$178.7M | $203.4M | — | −105.04% |
| 2024 | 2024-12-31 | −$382.1M | −$45.8M | — | −168.31% |
| 2023 | 2023-12-31 | −$336.3M | −$31.8M | — | −133.74% |
| 2022 | 2022-12-31 | −$304.5M | $5.9M | — | −63.74% |
| 2021 | 2021-12-31 | −$310.3M | −$116.7M | — | −98.89% |
| 2020 | 2020-12-31 | −$193.7M | −$126.8M | — | −252.62% |
| 2019 | 2019-12-31 | −$66.9M | — | — | −123.43% |
Ginkgo Bioworks Holdings quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$46.9M | −$6.6M | — | −232.65% |
| Q1 2026 | 2026-03-31 | −$48.6M | $10.5M | — | −249.66% |
| Q4 2025 | 2025-12-31 | −$47.7M | $8.5M | — | −88.38% |
| Q3 2025 | 2025-09-30 | −$31.6M | $87.0M | — | −81.38% |
| Q2 2025 | 2025-06-30 | −$40.3M | $71.1M | — | −102.96% |
| Q1 2025 | 2025-03-31 | −$59.1M | $36.8M | — | −154.70% |
| Q4 2024 | 2024-12-31 | −$56.1M | $5.1M | — | −128.05% |
| Q3 2024 | 2024-09-30 | −$118.6M | −$40.7M | — | −133.18% |
| Q2 2024 | 2024-06-30 | −$111.4M | −$24.4M | — | −198.24% |
| Q1 2024 | 2024-03-31 | −$96.0M | $14.1M | — | −252.92% |
| Q4 2023 | 2023-12-31 | −$61.3M | $68.9M | — | −176.31% |
| Q3 2023 | 2023-09-30 | −$77.9M | −$36.1M | — | −140.60% |
| Q2 2023 | 2023-06-30 | −$87.1M | $21.9M | — | −108.07% |
| Q1 2023 | 2023-03-31 | −$110.0M | −$86.5M | — | −136.34% |
| Q4 2022 | 2022-12-31 | −$130.2M | $40.5M | — | −132.45% |
| Q3 2022 | 2022-09-30 | −$41.8M | −$31.2M | — | −63.00% |
| Q2 2022 | 2022-06-30 | −$109.0M | −$50.0M | — | −75.36% |
| Q1 2022 | 2022-03-31 | −$23.5M | $46.6M | — | −13.94% |
| Q4 2021 | 2021-12-31 | −$170.7M | — | — | −114.92% |
| Q3 2021 | 2021-09-30 | −$10.7M | — | — | −13.75% |
| Q2 2021 | 2021-06-30 | −$58.9M | — | — | −135.08% |
| Q1 2021 | 2021-03-31 | −$70.1M | — | — | −158.89% |
Ginkgo Bioworks Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$193.7M to −$178.7M, a net increase of $14.9M. Ginkgo Bioworks Holdings's latest reported quarter, Q2 2026, generated −$46.9M in free cash flow, a decrease of $6.6M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo links laboratory data services with Lilly’s TuneLab platform
Ginkgo ($DNA) Bioworks entered an agreement to provide experimental data-generation services to companies using Lilly’s ($LLY) TuneLab AI drug-discovery platform. Its Datapoints offering will supply small-molecule and antibody developabilit ...
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...
